NYSE:RCUS - Arcus Biosciences Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $64.25
  • Forecasted Upside: 38.59 %
  • Number of Analysts: 7
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 7 Buy Ratings
  • 0 Strong Buy Ratings
$46.36
▼ -2.1 (-4.33%)

This chart shows the closing price for RCUS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Arcus Biosciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for RCUS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for RCUS

Analyst Price Target is $64.25
▲ +38.59% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Arcus Biosciences in the last 3 months. The average price target is $64.25, with a high forecast of $100.00 and a low forecast of $51.00. The average price target represents a 38.59% upside from the last price of $46.36.

This chart shows the closing price for RCUS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 7 investment analysts is to buy stock in Arcus Biosciences. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/5/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/3/2020
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/2/2020
  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/2/2021
  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/31/2021
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/29/2021
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/28/2021
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/27/2021

Latest Recommendations

  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/19/2021WedbushBoost Price TargetOutperform$52.00 ➝ $67.00High
11/19/2021CitigroupBoost Price TargetBuy$42.00 ➝ $53.00High
11/19/2021BarclaysBoost Price TargetOverweight$48.00 ➝ $60.00High
11/18/2021SVB LeerinkBoost Price TargetOutperform$68.00 ➝ $100.00High
11/9/2021BarclaysBoost Price TargetPositive ➝ Overweight$45.00 ➝ $48.00High
11/9/2021MizuhoBoost Price TargetBuy$43.00 ➝ $51.00High
8/6/2021SVB LeerinkBoost Price TargetOutperform$63.00 ➝ $68.00High
7/14/2021SVB LeerinkSet Price TargetBuy$28.40High
6/24/2021SVB LeerinkBoost Price TargetPositive ➝ Outperform$53.00 ➝ $63.00High
2/25/2021SVB LeerinkLower Price TargetOutperform$54.00 ➝ $53.00Medium
2/25/2021BarclaysBoost Price TargetOverweight$40.00 ➝ $45.00Medium
2/25/2021MizuhoBoost Price TargetBuy$40.00 ➝ $43.00Medium
1/26/2021SVB LeerinkBoost Price TargetOutperform$41.00 ➝ $54.00High
1/20/2021BenchmarkBoost Price TargetBuy$32.00 ➝ $51.00High
1/19/2021TruistBoost Price Target$45.00 ➝ $70.00Low
1/19/2021WedbushBoost Price TargetOutperform$48.00 ➝ $55.00Low
1/13/2021Cantor FitzgeraldBoost Price TargetPositive ➝ Overweight$39.00 ➝ $62.00Medium
11/24/2020Berenberg BankInitiated CoverageBuy$50.00 ➝ $50.00Medium
11/23/2020Evercore ISIInitiated CoverageOutperformHigh
11/6/2020SVB LeerinkLower Price TargetOutperform$44.00 ➝ $41.00Medium
8/10/2020WedbushReiterated RatingOutperformLow
8/10/2020SVB LeerinkBoost Price TargetOutperform$42.00 ➝ $44.00High
6/10/2020SunTrust BanksBoost Price TargetBuy$22.00 ➝ $45.00Low
6/2/2020CitigroupBoost Price Target$15.00 ➝ $41.00Low
5/29/2020SVB LeerinkReiterated RatingOutperform$21.00 ➝ $42.00High
5/27/2020WedbushBoost Price TargetOutperform$40.00 ➝ $48.00High
5/19/2020Cantor FitzgeraldReiterated RatingOverweightLow
5/14/2020MizuhoBoost Price TargetBuy$22.00 ➝ $40.00High
5/7/2020BarclaysReiterated RatingBuy$35.00High
5/6/2020WedbushBoost Price TargetOutperform$26.00 ➝ $40.00High
4/16/2020BTIG ResearchBoost Price Target$20.00 ➝ $34.00High
4/2/2020Cantor FitzgeraldInitiated CoverageOverweight$21.00High
4/1/2020SunTrust BanksBoost Price TargetBuy$20.00 ➝ $22.00High
3/4/2020BarclaysInitiated CoverageOverweight$24.00High
2/26/2020MizuhoReiterated RatingBuy$22.00Medium
12/18/2019MizuhoInitiated CoverageBuy$22.00High
11/12/2019SunTrust BanksInitiated CoverageBuy$20.00High
11/11/2019MizuhoReiterated RatingBuy$22.00Low
10/20/2019MizuhoReiterated RatingBuyMedium
9/26/2019MizuhoInitiated CoverageBuy$22.00High
6/5/2019CitigroupLower Price TargetBuy ➝ In-Line$25.00 ➝ $15.00Low
5/24/2019CitigroupReiterated RatingBuy ➝ Buy$25.00Low
5/3/2019SVB LeerinkReiterated RatingOutperformHigh
3/18/2019BTIG ResearchInitiated CoverageBuy$20.00Low
10/9/2018WedbushInitiated CoverageOutperform ➝ Outperform$22.00High
4/9/2018SVB LeerinkInitiated CoverageOutperform ➝ Outperform$21.00High
4/9/2018CitigroupInitiated CoverageBuy ➝ Buy$18.00High
4/9/2018The Goldman Sachs GroupInitiated CoverageNeutral ➝ Neutral$18.00High
(Data available from 11/27/2016 forward)

News Sentiment Rating

0.11 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/1/2021
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/31/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/30/2021
  • 1 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
7/30/2021
  • 0 very positive mentions
  • 4 positive mentions
  • 2 negative mentions
  • 2 very negative mentions
8/29/2021
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
9/28/2021
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/28/2021
  • 3 very positive mentions
  • 24 positive mentions
  • 6 negative mentions
  • 1 very negative mentions
11/27/2021

Current Sentiment

  • 3 very positive mentions
  • 24 positive mentions
  • 6 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Arcus Biosciences logo
Arcus Biosciences, Inc. engages in the development and commercialization of immunotherapies. It competes in the segments of the pharmaceutical, biotechnology and other related markets that develop immunotherapies for the treatment of cancer. The company was founded by Terry J. Rosen and Juan Carlos Jaen in 2015 and is headquartered in Hayward, CA.
Read More

Today's Range

Now: $46.36
Low: $44.02
High: $48.39

50 Day Range

MA: $36.71
Low: $31.38
High: $48.47

52 Week Range

Now: $46.36
Low: $22.36
High: $49.10

Volume

647,514 shs

Average Volume

577,390 shs

Market Capitalization

$3.26 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.94

Frequently Asked Questions

What sell-side analysts currently cover shares of Arcus Biosciences?

The following Wall Street sell-side analysts have issued stock ratings on Arcus Biosciences in the last twelve months: Barclays PLC, Benchmark Co., Cantor Fitzgerald, Citigroup Inc., Mizuho, SVB Leerink LLC, Truist, Wedbush, and Zacks Investment Research.
View the latest analyst ratings for RCUS.

What is the current price target for Arcus Biosciences?

8 Wall Street analysts have set twelve-month price targets for Arcus Biosciences in the last year. Their average twelve-month price target is $64.25, suggesting a possible upside of 38.6%. SVB Leerink LLC has the highest price target set, predicting RCUS will reach $100.00 in the next twelve months. Mizuho has the lowest price target set, forecasting a price of $51.00 for Arcus Biosciences in the next year.
View the latest price targets for RCUS.

What is the current consensus analyst rating for Arcus Biosciences?

Arcus Biosciences currently has 7 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe RCUS will outperform the market and that investors should add to their positions of Arcus Biosciences.
View the latest ratings for RCUS.

How do I contact Arcus Biosciences' investor relations team?

Arcus Biosciences' physical mailing address is 3928 Point Eden Way, Hayward CA, 94545. The company's listed phone number is (510) 694-6200 and its investor relations email address is [email protected] The official website for Arcus Biosciences is www.arcusbio.com.